Rafał Watrowski1, Christoph Jäger2, Johannes Forster3. 1. Department of Gynecology and Obstetrics, St. Josefskrankenhaus, Teaching Hospital of the University of Freiburg, Freiburg, Germany Rafal.Watrowski@gmx.at. 2. Department of Gynecology and Obstetrics, St. Josefskrankenhaus, Teaching Hospital of the University of Freiburg, Freiburg, Germany. 3. Department of Pediatrics, St. Josefskrankenhaus, Teaching Hospital of the University of Freiburg, Freiburg, Germany.
Abstract
AIM: To assess the impact of the use of intraoperative hemostatic gelatin-thrombin matrix (HM) (Floseal®, Baxter Healthcare) on transfusion rates and short-term perioperative outcomes in gynecological surgery. PATIENTS AND METHODS: In this retrospective, single-center study, we evaluated data of 215 patients (83 cases and 132 controls) undergoing extensive gynecological surgery (e.g. oncological procedures) with and without intraoperative HM application. RESULTS: Cases and controls did not differ according to age, preoperative hemoglobin (Hb) concentration, and Hb or C-reactive protein (CRP) levels at discharge. Patients receiving HM had significantly reduced operative (168 vs. 199 min, p=0.02) and hospitalization (9 vs. 14 days, p<0.001) times. The mean postoperative Hb drop (3.33 vs. 4.51 g/dl, p<0.001), and the mean postoperative increase in CRP (94.9 vs. 149.1 mg/l, p<0.001) were significantly less pronounced within the HM group. Despite more prevalent coagulopathy (48 vs. 31%, p=0.02), e.g. due to anticoagulant use (15.7 vs. 3%, p<0.001), patients treated using HM needed less frequent transfusions of packed red blood cells [odds ratio (OR)= 0.13, 95% confidence interval (CI)=0.07-0.24) and fresh frozen plasma (OR=0.51, 95% CI=0.24-1.05). In comparison to controls, the need for surgical revisions (OR 0.1, CI 95% 0.02-0.42) and intensive-care unit admissions (OR 0.15, 95% CI=0.08-0.30) was lower in patients treated with HM. CONCLUSION: To our knowledge, our study is the largest case-control study focusing on Floseal® use in gynecology. The use of HM was associated with significantly better short-term perioperative outcomes. Due to its local action, HM seems to be particularly useful in patients in which anticoagulant medication cannot be paused. Copyright
AIM: To assess the impact of the use of intraoperative hemostatic gelatin-thrombin matrix (HM) (Floseal®, Baxter Healthcare) on transfusion rates and short-term perioperative outcomes in gynecological surgery. PATIENTS AND METHODS: In this retrospective, single-center study, we evaluated data of 215 patients (83 cases and 132 controls) undergoing extensive gynecological surgery (e.g. oncological procedures) with and without intraoperative HM application. RESULTS: Cases and controls did not differ according to age, preoperative hemoglobin (Hb) concentration, and Hb or C-reactive protein (CRP) levels at discharge. Patients receiving HM had significantly reduced operative (168 vs. 199 min, p=0.02) and hospitalization (9 vs. 14 days, p<0.001) times. The mean postoperative Hb drop (3.33 vs. 4.51 g/dl, p<0.001), and the mean postoperative increase in CRP (94.9 vs. 149.1 mg/l, p<0.001) were significantly less pronounced within the HM group. Despite more prevalent coagulopathy (48 vs. 31%, p=0.02), e.g. due to anticoagulant use (15.7 vs. 3%, p<0.001), patients treated using HM needed less frequent transfusions of packed red blood cells [odds ratio (OR)= 0.13, 95% confidence interval (CI)=0.07-0.24) and fresh frozen plasma (OR=0.51, 95% CI=0.24-1.05). In comparison to controls, the need for surgical revisions (OR 0.1, CI 95% 0.02-0.42) and intensive-care unit admissions (OR 0.15, 95% CI=0.08-0.30) was lower in patients treated with HM. CONCLUSION: To our knowledge, our study is the largest case-control study focusing on Floseal® use in gynecology. The use of HM was associated with significantly better short-term perioperative outcomes. Due to its local action, HM seems to be particularly useful in patients in which anticoagulant medication cannot be paused. Copyright
Authors: Lindsay L Morgenstern Warner; Sean C Dowdy; Janice R Martin; Maureen A Lemens; Michaela E McGree; Amy L Weaver; Karl C Podratz; Jamie N Bakkum-Gamez Journal: Int J Gynecol Cancer Date: 2013-11 Impact factor: 3.437
Authors: Aarne Feldheiser; Anne Bar Yosef; Elena-Ioana Braicu; Tommaso Bonomo; Lutz Kaufner; Claudia Spies; Jalid Sehouli; Christina Fotopoulou; Klaus Pietzner Journal: Anticancer Res Date: 2015-03 Impact factor: 2.480
Authors: Francisco Raga; Magda Sanz-Cortes; Francisco Bonilla; Eva María Casañ; Fernando Bonilla-Musoles Journal: Fertil Steril Date: 2009-05-06 Impact factor: 7.329
Authors: Giuseppe Nasso; Felice Piancone; Raffaele Bonifazi; Vito Romano; Giuseppe Visicchio; Carlo Maria De Filippo; Barbara Impiombato; Flavio Fiore; Francesco Bartolomucci; Francesco Alessandrini; Giuseppe Speziale Journal: Ann Thorac Surg Date: 2009-11 Impact factor: 4.330
Authors: Saketh R Guntupalli; Alyse Brennecke; Kian Behbakht; Anna Tayebnejad; Christopher A Breed; Lisa Marie Babayan; Georgina Cheng; Amin A Ramzan; Lindsay J Wheeler; Bradley R Corr; Carolyn Lefkowits; Jeanelle Sheeder; Koji Matsuo; Dina Flink Journal: JAMA Netw Open Date: 2020-06-01